Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease.
Angenendt L, Kerkhoff A, Wiebe S, Mikesch JH, Rudat A, Wötzel F, Wenning C, Schliemann C, Kessler T, Schäfers M, Wardelmann E, Stelljes M, Berdel WE. Angenendt L, et al. Among authors: kerkhoff a. Ann Hematol. 2015 Jul;94(7):1241-3. doi: 10.1007/s00277-015-2353-8. Epub 2015 Mar 21. Ann Hematol. 2015. PMID: 25791243 No abstract available.
Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.
Schliemann C, Gutbrodt KL, Kerkhoff A, Pohlen M, Wiebe S, Silling G, Angenendt L, Kessler T, Mesters RM, Giovannoni L, Schäfers M, Altvater B, Rossig C, Grünewald I, Wardelmann E, Köhler G, Neri D, Stelljes M, Berdel WE. Schliemann C, et al. Among authors: kerkhoff a. Cancer Immunol Res. 2015 May;3(5):547-56. doi: 10.1158/2326-6066.CIR-14-0179. Epub 2015 Feb 11. Cancer Immunol Res. 2015. PMID: 25672398
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M. Meißner T, et al. Among authors: kerkhoff a. Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4):a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul. Cold Spring Harb Mol Case Stud. 2017. PMID: 28679691 Free PMC article.
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
Schultheis B, Reuter D, Ebert MP, Siveke J, Kerkhoff A, Berdel WE, Hofheinz R, Behringer DM, Schmidt WE, Goker E, De Dosso S, Kneba M, Yalcin S, Overkamp F, Schlegel F, Dommach M, Rohrberg R, Steinmetz T, Bulitta M, Strumberg D. Schultheis B, et al. Among authors: kerkhoff a. Ann Oncol. 2017 Oct 1;28(10):2429-2435. doi: 10.1093/annonc/mdx343. Ann Oncol. 2017. PMID: 28961832 Free article. Clinical Trial.
Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases.
Schliemann C, Kerkhoff A, Hesse P, Bröckling S, Hardes J, Streitbürger A, Andreou D, Gosheger G, Elges S, Wardelmann E, Hartmann W, Mesters R, Lenz G, Willich N, Kriz J, Eich H, Berdel WE, Kessler T. Schliemann C, et al. Among authors: kerkhoff a. PLoS One. 2018 May 22;13(5):e0197315. doi: 10.1371/journal.pone.0197315. eCollection 2018. PLoS One. 2018. PMID: 29787570 Free PMC article.
191 results